Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON3: rucaparib versus physician's choice in HRD metastatic castration-resistant prostate cancer
2016-003163-20Phase 3Unknown
- Sponsor
- Clovis Oncology
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Clovis Oncology. Primary endpoint: Radiographic progression-free survival. Status: unknown.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-003163-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003163-20.